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Background: Allergic bronchopulmonary aspergillosis (ABPA) in patients with CF is associated with frequent exacerbations and deterioration of
lung function. Oral corticosteroids are standard therapy for ABPA and are associated with severe side effects. Monthly pulses of high-dose
intravenous methylprednisolone (HDIVPM) are an effective therapy for autoimmune diseases with fewer side effects compared to oral prednisone,
implicating its use for patients with CF who suffer from ABPA.
Methods: 9 patients with CF and ABPA (4 male, 5 female, ages 7–36 years) received HDIVPM (10–15 mg/kg/d), for 3 days per month, and
itraconazole, until clinical and laboratory resolution of ABPA.
Results: All patients showed clinical and laboratory improvement (FEV1 increase, serum IgE levels and total eosinophil counts decrease) and
treatment was discontinued after 6–10 pulses. Adverse effects were minor and disappeared shortly after each IV pulse therapy.
Conclusion: High-dose IV-pulse methylprednisolone is an effective treatment for ABPA in CF with minor side effects.
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Allergic bronchopulmonary aspergillosis (ABPA) is a lung
hypersensitivity disease mediated by an allergic late-phase
inflammatory response to specific antigens of Aspergillus
fumigatus [1], characterized by clinical deterioration associated
with elevated serum IgE and precipitin levels and evidence of
immediate cutaneous reactivity to A. fumigatus. ABPA is
associated with frequent exacerbations and deterioration of lung
function. Respiratory colonization by A. fumigatus is common
in patients with CF [2] leading to sensitization to the fungus [3].☆ Presented at the European Cystic Fibrosis Society meeting in Prague,
June 13th, 2008.
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doi:10.1016/j.jcf.2009.04.008The prevalence of ABPA in patients with CF was reported to
range from 1 to 15% [4] and increases with the patient's age [5].
Early treatment of ABPA may ameliorate the progression of
lung disease and prevent deterioration to a severe fibrotic stage
as well as permanent lung damage [6–8]. The treatment of
ABPA includes systemic corticosteroids, usually oral predni-
sone [9], with a starting dose of 0.5–2 mg/kg/day for 2–4 weeks
followed by slow tapering off over 1–3 months. Often patients
with CF require prolonged therapy with oral corticosteroids,
which may induce severe side effects such as glucose
intolerance, growth suppression, cataracts and osteoporosis
that may lead to pathological fractures [10–13]. For this reason,
many clinicians add itraconazole (200–400 mg/day) to the
regimen to allow more rapid reduction in the steroid dose and
suppress the antigenic burden [9]. However, no controlled
studies have been carried out to show its efficacy. Furthermore,
therapy with conazols can augment steroid side effects.d by Elsevier B.V. All rights reserved.
Table 2
Presence of positive ABPA criteria prior to therapy.
IV pulse
methylprednisolone
Oral
prednisone
Clinical deterioration not responding to
antibiotic therapy
9/9 5/5
Mean total IgE, IU/ml (range) 542
(350–1213)
2495
(260–4660)
Mean eosinophils, mm3 (range) 302
(100–600)
924
(320–1780)
AF specific IgE, IU/ml (range) 1–240 5–N100
AF skin test positive 9/9 5/5
Aspergillus in sputum 7/9 4/5
Typical imaging (chest X-rays or CT) 9/9 5/5
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prednisolone are commonly used for the treatment of a number
of diseases with the purpose to reduce or eliminate the known
severe adverse effects related to prolonged systemic steroid
treatment. Successful outcome with monthly pulse high dose
steroids in a small number of patients with ABPAwas recently
reported [14].
The aim of this report is to describe our experience with
monthly pulses of IV high dose methylprednisolone in patients
with CF and ABPA. We also report the experience of patients
with CF and ABPA treated with oral prednisone at two different
CF Centers in Israel.
2. Patients and methods
Since 2002 all patients with CF treated at the Hadassah
Medical Center, Mount Scopus, who were diagnosed with
ABPA, received monthly IV pulse methylprednisolone therapy
(IV group). At the Schneider Children's Medical Center and the
Sheba Medical Center patients with CF and ABPAwere treated
with standard oral therapy (PO group).
Diagnosis of CF in all patients was based on typical clinical
presentation together with at least two positive sweat chloride
tests and/or two CF-causing CFTR mutations [15]. ABPA
diagnosis was based on the criteria published in the ABPA
consensus paper [16], that included 5 or more of the following:
(a) acute or subacute clinical deterioration not attributable to
another etiology; (b) total serum IgE concentration higher than
500 IU/ml;(c) immediate cutaneous reactivity to Aspergillus;
(d) presence of serum IgE antibodies to A. fumigatus;
(e) precipitins or IgG antibodies to A. fumigatus; (f) new or
recent pulmonary infiltrates, mucus plugging, or bronchiectasis
that has not cleared with antibiotics and physiotherapy.
3. Protocol
IV group: Patients with CF who were diagnosed with ABPA,
were treated with intravenous high dose methylprednisolone
once a month 10–15 mg/kg/day (max dose 1 g) for 3
consecutive days, until resolution of their clinical symptoms
and laboratory parameters (total serum IgE, specific IgE to
Aspergillus fumigatus, total eosinophil blood count and PFT).
PO group: Patients with CF and ABPAwere treated with oral
prednisone, starting with 0.5 to 2 mg/kg/day for 2–4 weeks
followed by tapering off over 4–12 weeks. If relapse was
observed (clinical deterioration and/or increased serum IgETable 1
Clinical characteristics of patients prior to steroid treatment.
IV pulse methylprednisolone Oral prednisone
N 9 5
Gender m/f 4/5 3/2
Mean age years (range) 17.1 (7–36) 12.7 (33.5–27)
PI/PS 8/1 4/1
Mean FEV1 % pred (range) 64.6 (41–87) 56 (39–86)
Mean BMI kg/m2 (range) PI: 16.7 (15–19) PI: 14.9, (14–16)
PS: 29 PS: 26levels) the dose of oral prednisone was increased. All patients
continue to receive oral steroids at the present time.
Antifungal therapy: All patients in both groups were also
treated with oral itraconazole (200–400 mg/day). However, one
patient, from the IV group, received voriconazole after 1 month
of itraconazole treatment due to side effects related to
itraconazole (elevation in liver enzymes). Antifungal treatment
was continued in all patients after concluding steroid therapy,
according to the treating physician's judgment.
4. Results
Nine patients (4 male, 5 female), mean age 17.1 years (range
7–36 years) received IV methylprednisolone therapy and 5
patients (3 male, 2 female), mean age 12.7 (range 3.5–27 years)
received PO prednisone therapy. The clinical characteristics of
the patients prior to therapy are shown in Table 1. Table 2
summarizes the ABPA criteria prior to therapy according to
treatment groups.
In the IV group, the patients showed clinical improvement
and their FEV1 increased significantly with reduction in serum
IgE levels already after the second course of therapy (Fig. 1a, b).
Treatment for ABPA was discontinued after 6 to 10 courses of
IV methylprednisolone therapy. None of the patients suffered
from severe side effects, however, a number of mild and
transient adverse events occurred, namely flushing, tiredness,
fatigue, agitation, somnolence and myalgia, all of which
disappeared three to four days after each IV pulse therapy.
None of the patients with no previous CF-related diabetes
developed hyperglycemia. An ACTH test was performed in one
of the patients after the 6th monthly course of IV therapy which
was normal. We continue to follow all the patients with monthly
examinations (PFTs, sputum culture, total and periodic specific
serum IgE levels), after conclusion of treatment. One of our
patients, who received 6 courses of IV therapy, suffered from
recurrent ABPA and received another course of monthly pulses
of high dose methylprednisolone leading to complete resolu-
tion. Itraconzole (or voriconazole in one patient) treatment
continued from 8 months to over 5 years.
All patients in the PO group showed clinical improvement
with 0.5–2 mg/kg/day of prednisone (Fig. 2a and b), however,
during the tapering down of the prednisone dose, 4 patients
experienced clinical deterioration which required renewing or
Fig. 1. a Change in FEV1% predicted in the IV methylprednisolone group.
b Change in serum IgE levels in the IV methylprednisolone group.
Table 3
Comparison of adverse effects in the two groups.
IV pulse
methylprednisolone
Oral
prednisone
Excessive weight gain (N10%) 1/9 3/5
Hypertension 0/9 2/5
Cushingoid facies 0/9 5/5
Hirsutism 0/9 1/5 (severe)
Acne 0/9 2/5
Emotional instability 1/9 (transient) 2/5 (persistent)
Depression 0/9 1/5 (severe)
Hyperglycemia (in non CFRD) 0/9 0/4
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was much longer and all continued to receive oral prednisone
during the time of data collection. In addition, upon tapering
down of PO steroid treatment, all patients started to suffer from
significant corticosteroid-induced side effects (Table 3). OneFig. 2. a Change in FEV1% predicted in the PO prednisone group. b Change in
serum IgE levels in the PO prednisone group.patient was switched to IV pulse methylprednisolone after
severe deterioration with oral prednisone and improved rapidly
after the second course. The decrease in total IgE values in the
PO group was variable (Fig. 2b).
Table 3 lists the steroid associated side effects. It shows that
in the PO group patients suffered from excessive weight gain,
hypertension, cushingoid facies, hirsutism, acne, emotional
instability and severe depression. None of the patients with no
previous CF-related diabetes developed hyperglycemia.5. Discussion
ABPA is characterized by a variety of clinical and immuno-
logic responses to antigens of A. fumigatus, present within CF
airways, which may induce additional harm to the respiratory
epithelial cell layer by inducing a severe inflammatory response
[17]. Possibly, because of the intimate association of the fungus
with the airway epithelium, only concomitant systemic steroid
and antifungal therapy was found to be effective for the treatment
of ABPA [9]. Prolonged oral steroid therapy is especially
problematic for patients with CF who are already predisposed
to diabetes, osteopaenia and growth retardation.
This report demonstrates that monthly pulses of high-dose
IV methylprednisolone therapy were an effective treatment for
CF patients with ABPA. It induced significantly less side effects
when compared with conventional oral therapy, furthermore,
patients treated with pulse IV methylprednisolone seemed to
respond faster to therapy.
Monthly pulses of high dose IV methylprednisolone are
commonly used for the treatment of diseases that require therapy
with prolonged high doses of corticosteroids such as rheumato-
logic, autoimmune, hematological, renal, dermatologic, and
ophthalmologic diseases, as well as many others [18–22]. The
aim is to provide the anti- inflammatory effect while reducing or
eliminating the known severe adverse effects derived from
prolonged systemic steroid treatment. Thomson et al. first
demonstrated the effectiveness of monthly pulses of high-dose
IVmethylprednisolone in four childrenwithCF and severeABPA
who relapsed after reduction in the dose of oral steroids and who
suffered from serious side effects after prolonged therapy [14].
Three of the four patients were completely cured, whereas one
returned to oral treatment due to severe malaise after each IV
monthly course.
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steroid dose throughout the treatment duration, which was
relatively short. None of the uncommon adverse effects
described previously to occur with high dose pulse steroid
therapy such as hypertension, hypokalemia, infections [23],
arrhythmias [23,24], alteration in mental status [23,25] and
hyperglycemia [25] were observed in our study. In our patients
only mild side effects occurred including weakness, flushing
and tiredness that disappeared shortly after the end of each pulse
therapy. Most importantly, none of the side effects described in
the PO group were detected. In contrast, the course of patients in
the PO group was characterized by relapses post reduction of
oral dose and remissions after increasing the dose, necessitating
prolonged steroid therapy. The patients suffered from a number
of side effects including excessive weight gain, hypertension,
cushingoid facies, hirsutism, acne, emotional instability and
severe depression.
A recently described alternative treatment for ABPA in
patients who suffer from steroid side effects is Omalizumab
[26–28], a humanized monoclonal antibody directed against
IgE that prevents its binding to high- and low-affinity receptors
on effector cells. Omalizumab was previously shown to
effectively improve asthma control in patients with a strong
allergic component [29,30]. However, more experience needs
to be obtained before recommending this expensive therapy
routinely in ABPA.
The major limitation of our report is its retrospective nature.
A further confounding factor is the fact that the two groups were
treated at different centers with different screening policy and
treatment protocols.
In conclusion, we have shown that IV monthly pulse high-
dose methylprednisolone therapy is effective and relatively safe
in patients with CF and ABPA. It is associated with short and
transient side effects which are reversible within a few days and
therefore may be considered as standard therapy for ABPA in
CF. Further controlled studies are needed to define the role of IV
monthly pulse methylprednisolone therapy in patients with CF
and ABPA, however, for those who suffer from severe side
effects on oral therapy, this might be a valid alternative.
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